Liquid biopsy developer Epic Sciences has brought on Myriad Genetics’ oncology chief, Lloyd Sanders, to be its new president and CEO.
Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.
Just weeks after kick-starting its phase 1 test, Arch Oncology gathered $50 million in financing to see its immuno-oncology asset through the clinic.
Researchers at Mount Sinai and IBM found a link between responses to some cancer treatments and mitochondria, the energy centers in cells.
British biotechs raised £182 million, showing VCs are continuing to invest in U.K. biotechs despite political uncertainty.
Appetite for biotech IPOs still appears high as Hookipa Pharma filed for a meaty public offering to boost its midstage cancer and infectious disease work.
The funding will support research intended to improve the chances that Inflazome will succeed in the clinic.
Bayer is teaming up with a Swedish digital health startup focused on boosting patient compliance with an internet-connected pillbox.
Swedish p53 cancer biotech Aprea Therapeutics has nabbed former Agios senior medical director Eyal Attar as its senior vice president and chief medical officer…
An FDA panel voted against clearance for Neuronix's transcranial magnetic stimulation device, which targets the brain’s memory and learning centers.